XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.15

+2.8%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (3911)	9/25/1997 1:16:00 PM
From: tom jones	of 17367

To all: McCamant on TV 22 Los Angeles today and did not mention Xoma even though he did talk about second tier biotech stocks doing well. This is a tricky profession if he says something bad about a company then management will not talk to him again and he can't tout all his stock picks each time he talks. But it seems to me he has been cooling off on Xoma. Maybe someone knows differently. Data safety monitoring board could only reccmmend three things when they looked at the meningococcemia data. 1. stop the trial because neuprex was very harmful to people receiving it. But we already knew it was safe. I don't think they can say if the drug is not working; they can't report data. 2. stop the trial because people not receiving neuprex are being harmed very much; moving to open label is the same here. So here I take it they didn't see any outright clear difference or harm to those not taking the drug. 3. continue the trial. Please comment. I know BPI works, from what I understand it is a natural part of our system. Xoma needs to get it to work somehow. I am going to have to see the printed results of their phase II trials before I reinvest in Xoma. Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next